These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8810346)

  • 1. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.
    Hembrough TA; Li L; Gonias SL
    J Biol Chem; 1996 Oct; 271(41):25684-91. PubMed ID: 8810346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
    Hembrough TA; Kralovich KR; Li L; Gonias SL
    Biochem J; 1996 Aug; 317 ( Pt 3)(Pt 3):763-9. PubMed ID: 8760360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines.
    Hembrough TA; Vasudevan J; Allietta MM; Glass WF; Gonias SL
    J Cell Sci; 1995 Mar; 108 ( Pt 3)():1071-82. PubMed ID: 7542667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
    Ranson M; Andronicos NM; O'Mullane MJ; Baker MS
    Br J Cancer; 1998 May; 77(10):1586-97. PubMed ID: 9635833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
    Hajjar KA; Hamel NM
    J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
    Gonias SL; Hembrough TA; Sankovic M
    Front Biosci; 2001 Nov; 6():D1403-11. PubMed ID: 11689350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
    Obermajer N; Doljak B; Kos J
    Mol Cancer; 2009 Oct; 8():88. PubMed ID: 19845941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
    Doljak B; Obermajer N; Jamnik P; Kos J
    Cancer Lett; 2008 Aug; 267(1):75-84. PubMed ID: 18433993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The topology of plasminogen binding and activation on the surface of human breast cancer cells.
    Andronicos NM; Ranson M
    Br J Cancer; 2001 Sep; 85(6):909-16. PubMed ID: 11556845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
    Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
    Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.
    López-Alemany R; Longstaff C; Hawley S; Mirshahi M; Fábregas P; Jardí M; Merton E; Miles LA; Félez J
    Am J Hematol; 2003 Apr; 72(4):234-42. PubMed ID: 12666133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand.
    Cheng XF; Bäck O; Nilsson TK; Nylander Lundqvist E; Pohl G; Wallén P
    Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):407-13. PubMed ID: 1332673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
    Bu G; Morton PA; Schwartz AL
    J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18.
    Kralovich KR; Li L; Hembrough TA; Webb DJ; Karns LR; Gonias SL
    J Protein Chem; 1998 Nov; 17(8):845-54. PubMed ID: 9988531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.